Galectin Therapeutics Reports The Outcome Of The Fourth Data And Safety Monitoring Board Meeting For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Portal Hypertension Caused By Non-Alcoholic SteatoHepatitis Live
Portfolio Pulse from Benzinga Newsdesk
Galectin Therapeutics, Inc. (NASDAQ:GALT) reported a positive outcome from its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, a Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. The study is a global effort that randomized 357 patients in 14 countries. Interim topline data from the Phase 2b portion of NAVIGATE is expected in Q4 2024.

October 03, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive outcome from the DSMB meeting for Galectin's NAVIGATE study could boost investor confidence in the company's research and development capabilities. However, the impact on the stock price may be limited as the interim topline data is expected in Q4 2024.
The positive outcome from the DSMB meeting indicates that the NAVIGATE study is progressing well, which could boost investor confidence in Galectin's research and development capabilities. However, the impact on the stock price may be limited in the short term as the interim topline data is expected in Q4 2024, which is quite far off.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100